Zobrazeno 1 - 10
of 336
pro vyhledávání: '"Immune checkpoint inhibitors (ICI)"'
Autor:
Reem A. Assal, Noha M. Elemam, Radwa Y. Mekky, Abdelrahman A. Attia, Aya Hesham Soliman, Asmaa Ibrahim Gomaa, Eleni K. Efthimiadou, Maria Braoudaki, Sherif Ashraf Fahmy, Rana A. Youness
Publikováno v:
Translational Oncology, Vol 45, Iss , Pp 101961- (2024)
Tumor microenvironment is an intricate web of stromal and immune cells creating an immune suppressive cordon around the tumor. In hepatocellular carcinoma (HCC), Tumor microenvironment is a formidable barrier towards novel immune therapeutic approach
Externí odkaz:
https://doaj.org/article/b97b1893d1e349859fc3e36bc60843bb
Autor:
Valérian Rivet, Vincent Sibaud, Jérémie Dion, Thibaut Volosov, Mélanie Biteau, Andréa Pastissier, Karen Delavigne, Pierre Cougoul, Odile Rauzy, Thibault Comont
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionImmune checkpoint inhibitors (ICIs) are used in several advanced malignancies and may cause various immune-related adverse events (irAEs). Among them, hematological irAEs are less described. Acquired amegakaryocytic thrombocytopenia (AAT)
Externí odkaz:
https://doaj.org/article/bba72c905eee4b4facc38b47d1aad356
Autor:
Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, Eric T. Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jérôme Dumortier, Mar Riveiro Barciela, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P. Sutter, Thorben W. Fründt, Ansgar W. Lohse, Samuel Huber, Johann von Felden, Marcial Sebode, Kornelius Schulze
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/5ae046b1286d49d4ae94c23b6785358b
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The tumor microenvironment (TME) is a heterogeneous ecosystem comprising cancer cells, immune cells, stromal cells, and various non-cellular components, all of which play critical roles in controlling tumor progression and response to immunotherapies
Externí odkaz:
https://doaj.org/article/1a6e86b05fb34a998a86e5ffa3a67e0b
Autor:
Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, Eric T. Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jérôme Dumortier, Mar Riveiro Barciela, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P. Sutter, Thorben W. Fründt, Ansgar W. Lohse, Samuel Huber, Johann von Felden, Marcial Sebode, Kornelius Schulze
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionImmune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune−related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the trea
Externí odkaz:
https://doaj.org/article/960f39270c0d494aa189b438dca4f6de
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/51d22490419e4016a9aca9c0c8ed0c6f
Autor:
Mohammed Safi, Chenxing Jin, Abdullah Aldanakh, Ping Feng, Henan Qin, Mohammed Alradhi, Lizhi Zhang, Junying Zhang, Salah Adlat, Yi Zhao, Jiwei Liu
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Cancer diagnoses and deaths among the elderly (65 +) are expected to increase significantly over the next decade. Immune checkpoint inhibitors specifically target ICI genes and enhance immune system function. However, poor outcome
Externí odkaz:
https://doaj.org/article/7c76561d6c834fa68950da3cc4f48908
Autor:
Roisin McMorrow, Giorgia Zambito, Alex Nigg, Karishma Lila, Thierry P. P. van den Bosch, Clemens W. G. M. Lowik, Laura Mezzanotte
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionThe location of T-cells during tumor progression and treatment provides crucial information in predicting the response in vivo.MethodsHere, we investigated, using our bioluminescent, dual color, T-cell reporter mouse, termed TbiLuc, T-cel
Externí odkaz:
https://doaj.org/article/0f75ebfaf13b4331997f2b66d1beefdf
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 1, p 414 (2023)
Immune checkpoint inhibitors (ICI) revolutionized cancer therapy by augmenting anti-tumor immunity via cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1/programmed death-ligand 1 (PD-1/PD-L1). However, this breakthrough is a
Externí odkaz:
https://doaj.org/article/373926153a6d4a53bc0c7b13c4f51d3e
Autor:
Muhammad Khan, Kunpeng Du, Meiling Ai, Baiyao Wang, Jie Lin, Anbang Ren, Chengcong Chen, Zhong Huang, Wenze Qiu, Yawei Yuan, Yunhong Tian
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundInhibitors of programmed cell death 1 (PD-1)/programmed cell death ligand 1(PD-L1) checkpoint have been approved for metastatic triple negative breast cancer (mTNBC) in patients positive for PD-L1 expression. Negative results from the recen
Externí odkaz:
https://doaj.org/article/6df406e3e4e74016beb5a23be13b6ed5